Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Beranger L"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Séverine Henrard, Florence Tubach, Lorene Zerah, Dominique Bonnet-Zamponi, Wade Thompson, Antoine Christiaens, Noémie Simon-Tillaux, Alan J. Sinclair, Benoit B. Boland, Yannis Slaouti-Jégou, Béranger Lekens
Publikováno v:
BMJ Open, Vol 13, Iss 11 (2023)
Introduction In older adults with type 2 diabetes (T2D), overtreatment with hypoglycaemic drugs (HDs: sulfonylureas, glinides and/or insulins) is frequent and associated with increased 1-year mortality. Deintensification of HD is thus a key issue, fo
Externí odkaz:
https://doaj.org/article/68690b8c861f4dd3ae53a89b58fbe69b
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Aude Kopp, Olivier Mangin, Laurène Gantzer, Béranger Lekens, Guy Simoneau, Manoro Ravelomanantsoa, John Evans, Jean-François Bergmann, Pierre Sellier
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 1, Pp 162-169 (2021)
Streptococcus pneumoniae, the main cause of community-acquired pneumonia (CAP), also leads to exacerbations, hospitalizations, and mortality in chronic obstructive pulmonary disease (COPD) and congestive heart failure (CHF). The risk of CAP is increa
Externí odkaz:
https://doaj.org/article/22fdf2b4b4d34da190f12cacbd663ac8
Autor:
Thomas Nedelec, PhD, Baptiste Couvy-Duchesne, PhD, Fleur Monnet, MSc, Timothy Daly, MPhil, Manon Ansart, PhD, Laurène Gantzer, MSc, Béranger Lekens, MSc, Stéphane Epelbaum, PhD, Carole Dufouil, PhD, Stanley Durrleman, PhD
Publikováno v:
The Lancet: Digital Health, Vol 4, Iss 3, Pp e169-e178 (2022)
Summary: Background: The identification of modifiable risk factors for Alzheimer's disease is paramount for early prevention and the targeting of new interventions. We aimed to assess the associations between health conditions diagnosed in primary ca
Externí odkaz:
https://doaj.org/article/9e8f317e994e4b35bef6a0aba39528cb
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jean Ferrières, Victoria Banks, Demetris Pillas, Francesco Giorgianni, Laurene Gantzer, Beranger Lekens, Lea Ricci, Margaux Dova-Boivin, Jean-Vannak Chauny, Guillermo Villa, Gaelle Désaméricq
Publikováno v:
PLoS ONE, Vol 16, Iss 8 (2021)
Background and aims Untreated Familial Hypercholesterolemia (FH) leads to premature morbidity and mortality. In France, its epidemiology and management are understudied in ambulatory care. We described the clinical profile, pharmacological management
Externí odkaz:
https://doaj.org/article/7d7ab775bcb648d7ba970f75d6c564c9
Autor:
Manon Ansart, Stéphane Epelbaum, Marion Houot, Thomas Nedelec, Béranger Lekens, Laurène Gantzer, Didier Dormont, Stanley Durrleman
Publikováno v:
Alzheimer’s & Dementia: Translational Research & Clinical Interventions, Vol 7, Iss 1, Pp n/a-n/a (2021)
Abstract Introduction We aim to understand how patients with Alzheimer's disease (AD) are treated by identifying in a longitudinal fashion the late‐life changes in patients’ medical history that precede and follow AD diagnosis. Methods We use pre
Externí odkaz:
https://doaj.org/article/a48e97d665d348b5ad3ebf264796932e
Publikováno v:
BMC Medical Research Methodology, Vol 16, Iss 1, Pp 1-14 (2016)
Abstract Background The difference in restricted mean survival time ( rmstD t ∗ $$ rmstD\left({t}^{\ast}\right) $$ ), the area between two survival curves up to time horizon t ∗ $$ {t}^{\ast } $$ , is often used in cost-effectiveness analyses to
Externí odkaz:
https://doaj.org/article/394fd3bb2f514c02bdfa64f4a5f46cef
Autor:
Béranger Lueza, Audrey Mauguen, Jean-Pierre Pignon, Oliver Rivero-Arias, Julia Bonastre, MAR-LC Collaborative Group
Publikováno v:
PLoS ONE, Vol 11, Iss 3, p e0150032 (2016)
OBJECTIVE:In economic evaluation, a commonly used outcome measure for the treatment effect is the between-arm difference in restricted mean survival time (rmstD). This study illustrates how different survival analysis methods can be used to estimate
Externí odkaz:
https://doaj.org/article/32be855ea8b34b3bb603d5655d6821eb